The European Medicines Agency is recommending approval of a new advanced therapy medicinal product which is intended for the repair of cartilage defects. The product had been available in some EU countries, but now it will be widely traded. ---Subscribe to MedNous to access this article--- Regenerative Medicine Company News Regulation & Policy
